1.26
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché CTXR Giù?
Forum
Previsione
Frazionamento azionario
Citius Pharmaceuticals Inc Borsa (CTXR) Ultime notizie
How Citius Pharmaceuticals Inc. (47N0) stock reacts to fiscal policiesJuly 2025 Big Picture & Trade Opportunity Analysis - Newser
Is Citius Pharmaceuticals Inc. (47N0) stock good for wealth creation2025 Major Catalysts & Weekly Sector Rotation Insights - Newser
CTXR: Analyst Jason Kolbert Maintains 'Buy' Rating with $6 Price Target | CTXR Stock News - GuruFocus
Citius Oncology Expands LYMPHIR™ Distribution to Turkey and Middle East Countries Through Exclusive Agreement with Er-Kim - The Malaysian Reserve
How supply shortages influence Citius Pharmaceuticals Inc. (47N0) stockWeekly Market Outlook & AI Powered Trade Plan Recommendations - Newser
How Citius Pharmaceuticals Inc. (47N0) stock responds to bond market2025 Investor Takeaways & AI Enhanced Trading Signals - Newser
Cutaneous T-cell Lymphoma Market Expected to Experience Major Growth by 2032, According to DelveInsight | Innate Pharma, Galderma R&D, Kyowa Kirin, Citius Pharma, Soligenix, 4SC AG, oligenix, Ligand - Barchart.com
Citius Oncology launches Lymphir treatment for rare lymphoma - NJBIZ
How Citius Pharmaceuticals Inc. (47N0) stock reacts to new regulations2025 Analyst Calls & Momentum Based Trading Signals - Newser
Is Citius Pharmaceuticals Inc. (47N0) stock vulnerable to rate hikesDollar Strength & Capital Efficiency Focused Ideas - Newser
Citius Oncology enters distribution services agreement with Cardinal Health - MSN
Why Citius Pharmaceuticals Inc. (47N0) stock is a must watch tickerWeekly Loss Report & Reliable Entry Point Trade Alerts - Newser
Citius Oncology Launches LYMPHIR, The First CTCL Systemic Therapy In Over 7 Years - Nasdaq
Citius Pharmaceuticals Launches LYMPHIR for T-Cell Lymphoma - MSN
Will Citius Pharmaceuticals Inc. (47N0) stock boost dividends furtherProduct Launch & Stepwise Trade Signal Implementation - Newser
How Citius Pharmaceuticals Inc. (47N0) stock moves in volatile trading sessions - Newser
CTORCitius Oncology, Inc. Latest Stock News & Market Updates - Stock Titan
Citius Pharmaceuticals, Inc. Launches LYMPHIR for CTCL Treatment - TradingView
Citius Oncology Announces U.S. Commercial Launch of LYMPHIR™, a Novel Cancer Immunotherapy for Cutaneous T-Cell Lymphoma (CTCL) - PR Newswire
Why Citius Pharmaceuticals Inc. stock remains resilientIPO Watch & AI Forecasted Entry/Exit Points - BỘ NỘI VỤ
Citius Oncology Deploys AI Platform to Amplify the Performance of its Commercial Team Ahead of LYMPHIR Launch - Aktiellt
Citius Oncology to Exhibit at the 67th American Society of Hematology (ASH) Annual Meeting - 富途牛牛
Butterfly Network, Citius Pharma Drive Biotech Momentum In After-Hours Trading - Nasdaq
Citius Oncology to advance LYMPHIR launch with AI technology By Investing.com - Investing.com Nigeria
Citius Oncology to Advance Commercial Launch of LYMPHIR™ with Verix AI Integration - Placera.se
Citius Oncology stock soars on expanded AI collaboration for LYMPHIR launch - Investing.com
Citius Oncology to advance LYMPHIR launch with AI technology - Investing.com India
Citius Oncology (Nasdaq: CTOR) taps Verix AI to support Q4 2025 LYMPHIR CTCL launch - Stock Titan
Can Citius Pharmaceuticals Inc. (47N0) stock sustain free cash flow - newser.com
How Citius Pharmaceuticals Inc. stock reacts to Fed rate cutsStop Loss & Weekly High Potential Stock Alerts - newser.com
Can Citius Pharmaceuticals Inc. (47N0) stock withstand sector downturns2025 Top Decliners & Long-Term Safe Investment Plans - newser.com
Is Citius Pharmaceuticals Inc. (47N0) stock good for long term investingMarket Activity Summary & Daily Entry Point Trade Alerts - newser.com
Visual analytics tools that track Citius Pharmaceuticals Inc. performanceJuly 2025 Volume & Free Technical Confirmation Trade Alerts - newser.com
Will Citius Pharmaceuticals Inc. stock deliver better than expected guidance2025 Key Highlights & Consistent Return Investment Signals - newser.com
Is Citius Pharmaceuticals Inc. stock attractive for growth ETFsDollar Strength & Free Reliable Trade Execution Plans - newser.com
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):